TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01085149

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Simvastatin
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: 10 mg simvastatin, slow release in socket of extracted tooth (single application only)
Study: NCT00612456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib eye drops formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib eye drops formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib eye drops formulation
Study: NCT01920165

Intervention type: OTHER
Intervention: Smoke-free legislation
Description: The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
Study: NCT02429076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylphenidate
Description: IV methylphenidate will be administered to induce emergence from general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV methylphenidate
Description: IV methylphenidate will be administered to induce emergence from general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: normal saline
Study: NCT03001687

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral supplementation with vitamin D
Description: Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood collection 3mL
Description: all patients will have hepcidin levels measured in the first 24 hours after admission and one week after

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blood collection 3mL
Description: all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
Study: NCT04977219

Intervention type: BEHAVIORAL
Intervention: Prism Adaptation Training
Description: Therapists administering PAT followed the protocol developed by the Kessler Foundation (2014).PAT sessions lasted approximately 30 minutes during which patients with left sided neglect don 20 diopter prism goggles deviating their visual field to the right while aiming their finger at a series of visual targets.
Study: NCT01537822

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic morcellator
Description: Morcellation will be performed with the HM (TRUCLEAR, Smith \& Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Resectoscope
Description: Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
Study: NCT02429076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Inhaled anesthetic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: IV anesthetic
Study: NCT04424589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: Myofascial release or induction (IMF) is a widely used manual therapy treatment involving specifically guided, low-load, long-lasting mechanical forces to manipulate the myofascial complex, aimed at restoring optimal length, decreasing pain, and improving function. The experimental group will receive 1 examination session and 6 myofascial induction sessions carried out by a physiotherapist specialized in orthopedic manual therapy, superficial and deep techniques will be applied in the cervical region, for spinal at the level of the lumbar square, sacroiliac region and upper trapezius. 2 sessions per week over the course of 3 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: The control group will receive 1 examination session and 6 simulated myofascial induction sessions, where a physiotherapist will apparently apply the same techniques and maneuvers of myofascial induction, however, they will not follow the basic principles of technique execution, which does a procedure with a placebo effect.
Study: NCT00469391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GI Sleeve Implantable weight loss device (EndoBarrier)
Description: device for weight loss
Study: NCT03326856

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Formulation
Study: NCT00469391

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Weight loss
Study: NCT00592644

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulse Dye laser (PDL)
Description: one-time PDL, in 10 subjects

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CO2 laser or other traditional surgeries
Description: once-time CO2 laser or other conventional surgeries, in other 10 subjects
Study: NCT04477018

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron bis-glycinate chelate and vitamin C
Description: 28 mg iron; 240 mg vitamin C

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron bis-glycinate chelate
Description: 28 mg iron only

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study: NCT03579862

Intervention type: OTHER
Intervention: Blood Draw

Intervention type: OTHER
Intervention: Blood Draw

Intervention type: OTHER
Intervention: Blood Draw
Study: NCT01183299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary salt intake

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Dietary salt intake
Study: NCT03550976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The low-GI diet and muscle training
Description: During the 12-28 weeks of pregnancy, the pregnant women received low-GI diet and exercise intervention.Every two weeks, the pregnant women were followed up to assess the dietary situation and analyze the body composition results.Collect birth outcomes
Study: NCT00956046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
Study: NCT00524017

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: given IV
Study: NCT02898298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Emotion Regulation Training
Description: Participants will receive a 3-session psycho-educative training on emotion regulation.
Study: NCT00956046

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)
Description: 0.5 mL, Intramuscular on Day 0 and Day 21
Study: NCT03163290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterolateral Hip Complex Exercises
Description: The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anteromedial Hip Complex Exercises
Description: The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
Study: NCT01265628

Intervention type: PROCEDURE
Intervention: perimetry
Description: automated static perimetry with adapted GATE strategy

Intervention type: PROCEDURE
Intervention: perimetry
Description: automated static perimetry with adapted GATE strategy

Intervention type: PROCEDURE
Intervention: perimetry
Description: automated static perimetry with adapted GATE strategy
Study: NCT04191928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Apixaban is an orally administered highly selective factor Xa inhibitor, belonging to the class of direct-acting oral anticoagulants (DOAC) along with rivaroxoban and edoxaban. Factor Xa is an essential mediator of the clotting pathway in humans. Apixaban is currently approved by the FDA for treatment of VTE, prophylaxis of DVT in patients undergoing knee and hip replacement surgeries and for reducing the risk of embolic stroke and systemic embolism in patients with nonvalvular atrial fibrillation.
Study: NCT02288416

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Undergo video-based intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Study: NCT02898298

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Positive Emotion Regulation Training
Description: Participants will receive a 3-session psycho-educative training on emotion regulation.
Study: NCT00426101

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrathecal therapy
Description: If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.~Methotrexate: \<1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, \>3 yrs 12 mg. Prednisolone: \<1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, \>3 yrs 10 mg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell transplant
Description: The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
Study: NCT03901976

Intervention type: DEVICE
Group type: OTHER
Intervention: bed exit detection
Description: bed exit detection to avoid patients fall
Study: NCT01184443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
Study: NCT01331850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 24 weeks
Study: NCT00537381

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
Study: NCT00694759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: 30 mg for 2 weeks, then 45 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 500mg twice daily for 1 week, then 1000 mg twice daily
Study: NCT01331850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 1000 mg or 1200 mg daily oral doses for 24 weeks
Study: NCT00694759

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: capsule twice daily
Study: NCT05486221

Intervention type: OTHER
Intervention: Extensive cardiologic work-up
Description: Specific 3D and 2D echocardiography measuring left ventricule and left atrial dimensions as well as longitudinal strain. 30 day prolonged ECG monitoring.
Study: NCT03403959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: light therapy
Description: 6 weeks morning treatment with bright light therapy in own home.
Study: NCT01066754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Fexofenadine Hydrochloride 180 mg Tablets
Study: NCT03559140

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at 2.5 oC (Cryotherapy group)
Description: Patients assigned to this group will receive a final irrigation (application of cryotherapy) with 5 mL cold (8oC) 17% EDTA followed with 20 mL cold (8oC) sterile saline solution delivered to the WL using a cold (8oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at 8oC (Cryotherapy )
Description: Patients assigned to this group receive a final irrigation (application of cryotherapy) with 5 mL cold (2.5oC) 17% EDTA followed with 20 mL cold (2.5oC) sterile saline solution delivered to the WL using a cold (2.5oC) sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Applied saline solution at room temperature (No cryotherapy)
Description: Patients assigned to this control group were treated identically to the experimental groups, except that they will receive a final irrigation ( application of irrigant at room temperature) with 5 mL (room temperature) 17% EDTA followed with 20 mL (room temperature) sterile saline solution delivered to the WL using a sterile microcannula attached to the Endo Vac System (Kerr Endo) for 5 minutes.
Study: NCT00725218

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline 5 ml injection 10 min prior to propofol administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Axetil
Description: Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
Study: NCT00731770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Advair 250
Description: 1 puff bid inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- matched
Description: 1 puff bid inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo 1 puff bid inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advair 250 - matched
Description: i puff bid inhaled
Study: NCT00923559

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual at Child Health Centre
Description: Treatment as usual (TAU) involved scheduled nurse calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The nurse is encouraged to promote attachment and to detect postnatal depressions. Mothers might be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment might be initiated by the nurse or the mother. This was registered at the end-point interview.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalytic treatment (MIP)
Description: MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. In the study, the analysts strived to recruit the baby for an emotional interchange, though this did not imply any belief that the infant would understand verbal communication. Rather, the analyst addressed the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst took care in enrolling the participant mother. This was to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her space to vent her own frustration, depression and anxiety.
Study: NCT03189615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single oral dose of 10 mg Lu AF35700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single oral dose of 10 mg Lu AF35700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF35700
Description: Single oral dose of 10 mg Lu AF35700
Study: NCT00811577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZX100
Description: AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
Study: NCT00847288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Monthly Review Arm
Description: Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly Review Arm
Description: Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
Study: NCT02360384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linaclotide
Description: Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Linaclotide
Description: Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FODMAP diet
Description: Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
Study: NCT02641769

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Stem Cell Transplantation
Description: intervention with transplantation of autologous purified stem cells
Study: NCT02436421

Intervention type: OTHER
Group type: OTHER
Intervention: Best Practice Alert based in the Electronic Medical Record

Intervention type: OTHER
Group type: OTHER
Intervention: Best Practice Alert based in the Electronic Medical Record

Intervention type: OTHER
Group type: OTHER
Intervention: Best Practice Alert based in the Electronic Medical Record
Study: NCT01150123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- low dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- High dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- High dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- High dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Group B streptococcus (GBS) vaccine- High dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Saline
Study: NCT02953379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMS Mometasone gel
Description: The patient should administer 2 spray in each nostril, once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mometasone spray nasal
Description: The patient should administer 2 spray in each nostril, once daily.
Study: NCT04094467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneous injection daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: 0.25 mg subcutaneous injection daily for 6 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: 0.1 mg subcutaneous injection daily for 12 days
Study: NCT02883894

Intervention type: OTHER
Intervention: Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9
Study: NCT03942991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articaine
Description: infiltration injection of 4%artpharmadent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepivacaine 2% Injection
Description: infiltration injection of 2% Mepecaine-L